105 related articles for article (PubMed ID: 31531954)
21. HER3 and LINC00052 interplay promotes tumor growth in breast cancer.
Salameh A; Fan X; Choi BK; Zhang S; Zhang N; An Z
Oncotarget; 2017 Jan; 8(4):6526-6539. PubMed ID: 28036286
[TBL] [Abstract][Full Text] [Related]
22. Affibody-Conjugated RALA Polymers Delivering Oligomeric 5-Fluorodeoxyuridine for Targeted Therapy of HER2 Overexpressing Gastric Cancer.
Zhang F; Yin J; Zhang C; Han M; Wang X; Fu S; Du J; Zhang H; Li W
Macromol Biosci; 2020 Jul; 20(7):e2000083. PubMed ID: 32558229
[TBL] [Abstract][Full Text] [Related]
23. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
24. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
[TBL] [Abstract][Full Text] [Related]
25. [Bacterial synthesis, purification, and solubilization of transmembrane segments of ErbB family members].
Goncharuk MV; Shul'ga AA; Ermoliuk IaS; Tkach EN; Goncharuk SA; Pustovalova IuE; Mineev KS; Bocharov ÉV; Maslennikov IV; Arsen'ev AS; Kirpichnikov MP
Mol Biol (Mosk); 2011; 45(5):892-902. PubMed ID: 22393787
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
27. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
28. Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.
Nishimura Y; Mimura W; Mohamed Suffian IF; Amino T; Ishii J; Ogino C; Kondo A
J Biochem; 2013 Mar; 153(3):251-6. PubMed ID: 23235317
[TBL] [Abstract][Full Text] [Related]
29. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
30. Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.
Galbiati E; Cassani M; Verderio P; Martegani E; Colombo M; Tortora P; Mazzucchelli S; Prosperi D
Bioconjug Chem; 2015 Apr; 26(4):680-9. PubMed ID: 25741889
[TBL] [Abstract][Full Text] [Related]
31. Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy.
Biri-Kovács B; Adorján A; Szabó I; Szeder B; Bősze S; Mező G
Biomolecules; 2020 Jan; 10(2):. PubMed ID: 31991749
[TBL] [Abstract][Full Text] [Related]
32. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
33. Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.
Jeyarajan S; Xavier J; Rao NM; Gopal V
Int J Nanomedicine; 2010 Oct; 5():725-33. PubMed ID: 21042418
[TBL] [Abstract][Full Text] [Related]
34. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
[TBL] [Abstract][Full Text] [Related]
35. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.
Ren XR; Wang J; Osada T; Mook RA; Morse MA; Barak LS; Lyerly HK; Chen W
Breast Cancer Res; 2015 Feb; 17(1):20. PubMed ID: 25849870
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
37. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling.
Teng Y; Pi W; Wang Y; Cowell JK
Oncogene; 2016 Sep; 35(35):4633-40. PubMed ID: 26804171
[TBL] [Abstract][Full Text] [Related]
38. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
39. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
40. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
